This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JZP-416

Jazz Pharmaceuticals plc

Drug Names(s): Asparec, AZP-02, mPEG-r-crisantaspase, Pegylated recombinant Erwinia chrysanthemi L-asparaginase

Description: Asparec is a PEGylated recombinant L-asparaginase derived from Erwinia chrysanthemi.

Deal Structure: Aliz and EUSA
In February 2012, Aliz announced the signing of a licensing agreement with EUSA Pharma for ASPAREC. Pursuant to the agreement, EUSA will be responsible for the development and worldwide commercialization of ASPAREC. In return, Aliz has received an upfront payment, and will be entitled to additional regulatory milestone payments and royalties on sales. The companies have not disclosed further financial information.

EUSA and Jazz
In April 2012, Jazz and EUSA announced that the companies have signed a definitive agreement under which Jazz has agreed to acquire EUSA for $650 million in cash and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze (asparaginase Erwinia chrysanthemi), achieving a specified U.S. net sales target in 2013. In June 2012, Jazz announced the closing of its acquisition of EUSA Pharma.

Aliz and Jazz
In May 2016, Aliz Pharma II announced that Jazz Pharmaceuticals...See full deal structure in Biomedtracker


JZP-416 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug